{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:03:43Z","timestamp":1789981423199,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Medical and Health Science and Technology Program","award":["2023KY389"],"award-info":[{"award-number":["2023KY389"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-026-06421-9","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:25:18Z","timestamp":1787840718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting METTL3\/m6A\/SOCS3 axis reprograms tumor-associated macrophage polarization to potentiate the efficacy of anti-PD-1 therapy in multiple myeloma"],"prefix":"10.1007","volume":"83","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengni","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinle","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7204-7679","authenticated-orcid":false,"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"6421_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397:410\u2013427. https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5","journal-title":"Lancet"},{"key":"6421_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.clml.2021.07.013","volume":"21","author":"LL George","year":"2021","unstructured":"George LL, Malik MN, Miller EJ, Hicks K, Khanam R, Saterehaseman A, McNichol M, Anwer F (2021) Special considerations for supportive care and management of complications in elderly patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 21:812\u2013822. https:\/\/doi.org\/10.1016\/j.clml.2021.07.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6421_CR3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3390\/cancers12082113","volume":"12","author":"S Rasch","year":"2020","unstructured":"Rasch S, Lund T, Asmussen JT, Lerberg Nielsen A, Faebo Larsen R, \u00d8sterheden Andersen M, Abildgaard N (2020) Multiple myeloma associated bone disease. Cancers (Basel) 12:2113. https:\/\/doi.org\/10.3390\/cancers12082113","journal-title":"Cancers (Basel)"},{"key":"6421_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12185-024-03849-2","volume":"120","author":"F Ohara","year":"2024","unstructured":"Ohara F, Suzuki A, Suzuki N, Kanematsu T, Okamoto S, Tamura S, Kiyoi H, Matsushita T, Katsumi A (2024) Newly diagnosed multiple myeloma with bleeding and coagulation abnormalities caused by a thrombin-inhibiting substance. Int J Hematol 120:743\u2013749. https:\/\/doi.org\/10.1007\/s12185-024-03849-2","journal-title":"Int J Hematol"},{"key":"6421_CR5","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/s1470-2045(23)00223-1","volume":"24","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ, Kastritis E, Garderet L, Gozzetti A, van de Donk N, Weisel KC, Badros AZ, Beksac M, Hillengass J, Mohty M, Ho PJ, Ntanasis-Stathopoulos I, Mateos MV, Richardson P, Blade J, Moreau P, San-Miguel J, Munshi N, Rajkumar SV, Durie BGM, Ludwig H, Terpos E (2023) Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol 24:e293\u2013e311. https:\/\/doi.org\/10.1016\/s1470-2045(23)00223-1","journal-title":"Lancet Oncol"},{"key":"6421_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, Xu X, Liu H, Zhao X, Yang C, Fu R (2023) Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol 12:99. https:\/\/doi.org\/10.1186\/s40164-023-00456-5","journal-title":"Exp Hematol Oncol"},{"key":"6421_CR7","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","volume":"30","author":"B Le Calvez","year":"2021","unstructured":"Le Calvez B, Moreau P, Touzeau C (2021) Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. Expert Opin Investig Drugs 30:965\u2013973. https:\/\/doi.org\/10.1080\/13543784.2021.1955103","journal-title":"Expert Opin Investig Drugs"},{"key":"6421_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/cancers14010113","volume":"14","author":"O Alkharabsheh","year":"2021","unstructured":"Alkharabsheh O, Trisel Z, Badami S, Aljama MA, Sidiqi MH (2021) Checkpoint inhibitors in multiple myeloma: intriguing potential and unfulfilled promises. Cancers (Basel) 14:113. https:\/\/doi.org\/10.3390\/cancers14010113","journal-title":"Cancers (Basel)"},{"key":"6421_CR9","doi-asserted-by":"publisher","first-page":"e001341","DOI":"10.1136\/jitc-2020-001341","volume":"9","author":"C Li","year":"2021","unstructured":"Li C, Xu X, Wei S, Jiang P, Xue L, Wang J (2021) Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer 9:e001341. https:\/\/doi.org\/10.1136\/jitc-2020-001341","journal-title":"J Immunother Cancer"},{"key":"6421_CR10","doi-asserted-by":"publisher","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","volume":"14","author":"U Basak","year":"2023","unstructured":"Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S, Nayak D, Kaushik S, Das T, Sa G (2023) Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol 14:1295257. https:\/\/doi.org\/10.3389\/fimmu.2023.1295257","journal-title":"Front Immunol"},{"key":"6421_CR11","doi-asserted-by":"publisher","first-page":"888713","DOI":"10.3389\/fimmu.2022.888713","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao J, Liang Y, Wang L (2022) Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol 13:888713. https:\/\/doi.org\/10.3389\/fimmu.2022.888713","journal-title":"Front Immunol"},{"key":"6421_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, Bu T, Xiao Q, Ding K (2025) Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther 10:268. https:\/\/doi.org\/10.1038\/s41392-025-02325-5","journal-title":"Signal Transduct Target Ther"},{"key":"6421_CR13","doi-asserted-by":"publisher","first-page":"2600701","DOI":"10.1080\/15384047.2025.2600701","volume":"27","author":"PP Jordanides","year":"2026","unstructured":"Jordanides PP, Jagadeesha S, Upadhaya P, Ryan NM, Anderson K, Lamenza FF, Shrestha S, Siddiqui A, Bopp AR, Pracha SH, Roth P, Kehres R, Mo X, Oghumu S (2026) PI3K\u03b3 inhibition drives M1 macrophage differentiation and synergizes with PD-L1 blockade to improve survival in poorly immunogenic head and neck squamous cell carcinoma. Cancer Biol Ther 27:2600701. https:\/\/doi.org\/10.1080\/15384047.2025.2600701","journal-title":"Cancer Biol Ther"},{"key":"6421_CR14","doi-asserted-by":"publisher","first-page":"217935","DOI":"10.1016\/j.canlet.2025.217935","volume":"631","author":"C Wang","year":"2025","unstructured":"Wang C, Han L, Zhang J, Ji Q, Guo X, Li Y, Li S, He J, He F, Dai W, Li M, Yu J, Chen D, Gong Y, Xie C (2025) Radiotherapy in combination with PD-1 and TIGIT blockade mediate antitumor abscopal effects and immune memory via CD8+ T cells. Cancer Lett 631:217935. https:\/\/doi.org\/10.1016\/j.canlet.2025.217935","journal-title":"Cancer Lett"},{"key":"6421_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41423-023-01112-y","volume":"21","author":"F Luo","year":"2024","unstructured":"Luo F, Li H, Ma W, Cao J, Chen Q, Lu F, Qiu M, Zhou P, Xia Z, Zeng K, Zhan J, Zhou T, Luo Q, Pan W, Zhang L, Lin C, Huang Y, Zhang L, Yang D, Zhao H (2024) The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cell Mol Immunol 21:60\u201379. https:\/\/doi.org\/10.1038\/s41423-023-01112-y","journal-title":"Cell Mol Immunol"},{"key":"6421_CR16","doi-asserted-by":"publisher","first-page":"874589","DOI":"10.3389\/fimmu.2022.874589","volume":"13","author":"Y Pu","year":"2022","unstructured":"Pu Y, Ji Q (2022) Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression. Front Immunol 13:874589. https:\/\/doi.org\/10.3389\/fimmu.2022.874589","journal-title":"Front Immunol"},{"key":"6421_CR17","doi-asserted-by":"publisher","first-page":"802143","DOI":"10.3389\/fsurg.2021.802143","volume":"8","author":"X Zheng","year":"2021","unstructured":"Zheng X, Shao J, Wei S, Gu Y, Qian J (2021) Prognostic significance of SOCS3 in patients with solid tumors: a meta-analysis. Front Surg 8:802143. https:\/\/doi.org\/10.3389\/fsurg.2021.802143","journal-title":"Front Surg"},{"key":"6421_CR18","doi-asserted-by":"publisher","first-page":"112262","DOI":"10.1016\/j.biopha.2021.112262","volume":"144","author":"L Dai","year":"2021","unstructured":"Dai L, Li Z, Tao Y, Liang W, Hu W, Zhou S, Fu X, Wang X (2021) Emerging roles of suppressor of cytokine signaling 3 in human cancers. Biomed Pharmacother 144:112262. https:\/\/doi.org\/10.1016\/j.biopha.2021.112262","journal-title":"Biomed Pharmacother"},{"key":"6421_CR19","doi-asserted-by":"publisher","first-page":"1088542","DOI":"10.3389\/fimmu.2023.1088542","volume":"14","author":"X Li","year":"2023","unstructured":"Li X, Yang Z, Chen B, Gu L, Tian G, Sui X (2023) SOCS3 as a potential driver of lung metastasis in colon cancer patients. Front Immunol 14:1088542. https:\/\/doi.org\/10.3389\/fimmu.2023.1088542","journal-title":"Front Immunol"},{"key":"6421_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s13402-023-00896-5","volume":"47","author":"IH Jeong","year":"2024","unstructured":"Jeong IH, Yun JK, Jin JO, Hong JH, Lee JY, Lee GD, Lee PC (2024) E3 ligase SOCS3 regulates NOD2 expression by ubiquitin proteasome system in lung cancer progression. Cell Oncol (Dordr) 47:819\u2013832. https:\/\/doi.org\/10.1007\/s13402-023-00896-5","journal-title":"Cell Oncol (Dordr)"},{"key":"6421_CR21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.2174\/0109298665245603231106050224","volume":"30","author":"X Li","year":"2023","unstructured":"Li X, Peng B, Li J, Tian M, He L (2023) Unleashing breast cancer progression: miR-455-5p\u2019s targeting of SOCS3 drives proliferation, migration, and invasion. Protein Pept Lett 30:992\u20131000. https:\/\/doi.org\/10.2174\/0109298665245603231106050224","journal-title":"Protein Pept Lett"},{"key":"6421_CR22","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s13577-022-00715-3","volume":"35","author":"A Al Saqri","year":"2022","unstructured":"Al Saqri A, Malgundkar SH, Al Kindi F, Gupta I, Al Moundhri M, Tamimi Y (2022) SOCS3 gene silencing does not occur through methylation and mutations in gastric cancer. Hum Cell 35:1114\u20131125. https:\/\/doi.org\/10.1007\/s13577-022-00715-3","journal-title":"Hum Cell"},{"key":"6421_CR23","doi-asserted-by":"publisher","first-page":"155558","DOI":"10.1016\/j.prp.2024.155558","volume":"262","author":"A Jafarzadeh","year":"2024","unstructured":"Jafarzadeh A, Zandvakili R, Jafarzadeh Z, Nemati M (2024) Dysregulated expression of the suppressors of cytokine signaling (SOCS) contributes to the development of prostate cancer. Pathol Res Pract 262:155558. https:\/\/doi.org\/10.1016\/j.prp.2024.155558","journal-title":"Pathol Res Pract"},{"key":"6421_CR24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/cas.13194","volume":"108","author":"S Chikuma","year":"2017","unstructured":"Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A (2017) Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci 108:574\u2013580. https:\/\/doi.org\/10.1111\/cas.13194","journal-title":"Cancer Sci"},{"key":"6421_CR25","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s12033-023-01034-0","volume":"66","author":"J Ni","year":"2024","unstructured":"Ni J, Xi X, Xiao S, Xiao X (2024) Tumor cell-derived exosomal miR-191-5p activates M2-subtype macrophages through SOCS3 to facilitate breast cancer. Mol Biotechnol 66:1314\u20131325. https:\/\/doi.org\/10.1007\/s12033-023-01034-0","journal-title":"Mol Biotechnol"},{"key":"6421_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12916-023-03086-0","volume":"21","author":"Q Wang","year":"2023","unstructured":"Wang Q, Shi Q, Wang Z, Lu J, Hou J (2023) Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma. BMC Med 21:377. https:\/\/doi.org\/10.1186\/s12916-023-03086-0","journal-title":"BMC Med"},{"key":"6421_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.4161\/epi.6.8.16167","volume":"6","author":"S Wilop","year":"2011","unstructured":"Wilop S, van Gemmeren TB, Lentjes MH, van Engeland M, Herman JG, Br\u00fcmmendorf TH, Jost E, Galm O (2011) Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. Epigenetics 6:1047\u20131052. https:\/\/doi.org\/10.4161\/epi.6.8.16167","journal-title":"Epigenetics"},{"key":"6421_CR28","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","volume":"33","author":"L Lin","year":"2019","unstructured":"Lin L, Cao L, Liu Y, Wang K, Zhang X, Qin X, Zhao D, Hao J, Chang Y, Huang X, Liu B, Zhang J, Lu J, Ge Q (2019) B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3. Leukemia 33:1475\u20131486. https:\/\/doi.org\/10.1038\/s41375-018-0331-6","journal-title":"Leukemia"},{"key":"6421_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3324\/haematol.2012.065607","volume":"98","author":"P Liang","year":"2013","unstructured":"Liang P, Cheng SH, Cheng CK, Lau KM, Lin SY, Chow EY, Chan NP, Ip RK, Wong RS, Ng MH (2013) Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica 98:288\u2013295. https:\/\/doi.org\/10.3324\/haematol.2012.065607","journal-title":"Haematologica"},{"key":"6421_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.thj.6200565","volume":"5","author":"E Usui","year":"2004","unstructured":"Usui E, Nishii K, Katayama N, Lorenzo VF, Chen F, Monma F, Otsuki T, Shiku H (2004) Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells. Hematol J 5:505\u2013512. https:\/\/doi.org\/10.1038\/sj.thj.6200565","journal-title":"Hematol J"},{"key":"6421_CR31","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00277-023-05283-6","volume":"102","author":"X Huang","year":"2023","unstructured":"Huang X, Yang Z, Li Y, Long X (2023) m6A methyltransferase METTL3 facilitates multiple myeloma cell growth through the m6A modification of BZW2. Ann Hematol 102:1801\u20131810. https:\/\/doi.org\/10.1007\/s00277-023-05283-6","journal-title":"Ann Hematol"},{"key":"6421_CR32","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.7150\/ijbs.64943","volume":"18","author":"T Yu","year":"2022","unstructured":"Yu T, Yao L, Yin H, Teng Y, Hong M, Wu Q (2022) ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and myeloma stem cell phenotype. Int J Biol Sci 18:2235\u20132248. https:\/\/doi.org\/10.7150\/ijbs.64943","journal-title":"Int J Biol Sci"},{"key":"6421_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2147\/copd.s398289","volume":"18","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang L, Yan F, Yang M, Gao H, Zeng Y (2023) METTL3 mediated m6A methylation involved in epithelial-mesenchymal transition by targeting SOCS3\/STAT3\/SNAI1 in cigarette smoking-induced COPD. Int J Chron Obstruct Pulmon Dis 18:1007\u20131017. https:\/\/doi.org\/10.2147\/copd.s398289","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"6421_CR34","doi-asserted-by":"publisher","first-page":"116809","DOI":"10.1016\/j.jep.2023.116809","volume":"317","author":"Y Chen","year":"2023","unstructured":"Chen Y, Miao X, Xiang Y, Kuai L, Ding X, Ma T, Li B, Fan B (2023) Qinzhu Liangxue inhibits IL-6-induced hyperproliferation and inflammation in HaCaT cells by regulating METTL14\/SOCS3\/STAT3 axis. J Ethnopharmacol 317:116809. https:\/\/doi.org\/10.1016\/j.jep.2023.116809","journal-title":"J Ethnopharmacol"},{"key":"6421_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13008-025-00145-1","volume":"20","author":"H Yang","year":"2025","unstructured":"Yang H, He Y, Qu F, Zhu J, Deng L, Jiang F, Wu X, Chen Y, Kashif A, Wang X (2025) Maraviroc enhances Bortezomib sensitivity in multiple myeloma by inhibiting M2 macrophage polarization via PI3K\/AKT\/RhoA signaling pathway in macrophages. Cell Div 20:5. https:\/\/doi.org\/10.1186\/s13008-025-00145-1","journal-title":"Cell Div"},{"key":"6421_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","volume":"85","author":"WL Thuya","year":"2025","unstructured":"Thuya WL, Cao Y, Ho PC, Wong AL, Wang L, Zhou J, Nicot C, Goh BC (2025) Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy. Cytokine Growth Factor Rev 85:26\u201342. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.01.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"6421_CR37","doi-asserted-by":"publisher","first-page":"153574","DOI":"10.1016\/j.phymed.2021.153574","volume":"87","author":"YY Jung","year":"2021","unstructured":"Jung YY, Um JY, Nasif O, Alharbi SA, Sethi G, Ahn KS (2021) Blockage of the JAK\/STAT3 signaling pathway in multiple myeloma by leelamine. Phytomedicine 87:153574. https:\/\/doi.org\/10.1016\/j.phymed.2021.153574","journal-title":"Phytomedicine"},{"key":"6421_CR38","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s12013-024-01562-9","volume":"83","author":"X Xu","year":"2025","unstructured":"Xu X, Xu Z, Cai Y, Chen X, Huang C (2025) CKIP-1 inhibits M2 macrophage polarization to suppress the progression of gastric cancer by inactivating JAK\/STAT3 signaling. Cell Biochem Biophys 83:1289\u20131298. https:\/\/doi.org\/10.1007\/s12013-024-01562-9","journal-title":"Cell Biochem Biophys"},{"key":"6421_CR39","doi-asserted-by":"publisher","first-page":"113387","DOI":"10.1016\/j.intimp.2024.113387","volume":"143","author":"Y Qi","year":"2024","unstructured":"Qi Y, Li R, Han M (2024) Tumor-associated macrophages induce epithelial-mesenchymal transition and promote lung metastasis in breast cancer by activating the IL-6\/STAT3\/TGM2 axis. Int Immunopharmacol 143:113387. https:\/\/doi.org\/10.1016\/j.intimp.2024.113387","journal-title":"Int Immunopharmacol"},{"key":"6421_CR40","doi-asserted-by":"publisher","first-page":"e2203973","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"Tang B, Zhu J, Wang Y, Chen W, Fang S, Mao W, Xu Z, Yang Y, Weng Q, Zhao Z, Chen M, Ji J (2023) Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti-PD-1\/L1 response. Adv Sci (Weinh) 10:e2203973. https:\/\/doi.org\/10.1002\/advs.202203973","journal-title":"Adv Sci (Weinh)"},{"key":"6421_CR41","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s10565-021-09690-1","volume":"39","author":"F Che","year":"2023","unstructured":"Che F, Ye X, Wang Y, Wang X, Ma S, Tan Y, Mao Y, Luo Z (2023) METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m6A-dependent manner. Cell Biol Toxicol 39:2033\u20132050. https:\/\/doi.org\/10.1007\/s10565-021-09690-1","journal-title":"Cell Biol Toxicol"},{"key":"6421_CR42","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1007\/s11010-023-04906-w","volume":"479","author":"J Bao","year":"2024","unstructured":"Bao J, Xu T, Wang W, Xu H, Chen X, Xia R (2024) N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1. Mol Cell Biochem 479:3077\u20133089. https:\/\/doi.org\/10.1007\/s11010-023-04906-w","journal-title":"Mol Cell Biochem"},{"key":"6421_CR43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s10238-025-01624-z","volume":"25","author":"G Wang","year":"2025","unstructured":"Wang G, Wu W, He D, Wang J, Kong H, Wu W (2025) N6-methyladenosine-mediated upregulation of H19 promotes resistance to bortezomib by modulating the miR-184\/CARM1 axis in multiple myeloma. Clin Exp Med 25:102. https:\/\/doi.org\/10.1007\/s10238-025-01624-z","journal-title":"Clin Exp Med"},{"key":"6421_CR44","doi-asserted-by":"publisher","first-page":"104861","DOI":"10.1016\/j.critrevonc.2025.104861","volume":"214","author":"Y Yao","year":"2025","unstructured":"Yao Y, Tao G, Xie D, Xu Y, Li L (2025) Effect of JAK\/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer. Crit Rev Oncol Hematol 214:104861. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104861","journal-title":"Crit Rev Oncol Hematol"},{"key":"6421_CR45","doi-asserted-by":"publisher","first-page":"606368","DOI":"10.3389\/fonc.2020.606368","volume":"10","author":"L Yamamoto","year":"2020","unstructured":"Yamamoto L, Amodio N, Gulla A, Anderson KC (2020) Harnessing the immune system against multiple myeloma: challenges and opportunities. Front Oncol 10:606368. https:\/\/doi.org\/10.3389\/fonc.2020.606368","journal-title":"Front Oncol"},{"key":"6421_CR46","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.3390\/nano13152225","volume":"13","author":"WS Yun","year":"2023","unstructured":"Yun WS, Kim J, Lim DK, Kim DH, Jeon SI, Kim K (2023) Recent studies and progress in the intratumoral administration of nano-sized drug delivery systems. Nanomaterials (Basel) 13:2225. https:\/\/doi.org\/10.3390\/nano13152225","journal-title":"Nanomaterials (Basel)"},{"key":"6421_CR47","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41375-021-01127-2","volume":"35","author":"K Alhallak","year":"2021","unstructured":"Alhallak K, Sun J, Wasden K, Guenthner N, O\u2019Neal J, Muz B, King J, Kohnen D, Vij R, Achilefu S, DiPersio JF, Azab AK (2021) Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia 35:2346\u20132357. https:\/\/doi.org\/10.1038\/s41375-021-01127-2","journal-title":"Leukemia"},{"key":"6421_CR48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, Webster NA, Andrews B, Fosbeary R, Guest P, Irigoyen N, Eleftheriou M, Gozdecka M, Dias JML, Bannister AJ, Vick B, Jeremias I, Vassiliou GS, Rausch O, Tzelepis K, Kouzarides T (2021) Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593:597\u2013601. https:\/\/doi.org\/10.1038\/s41586-021-03536-w","journal-title":"Nature"},{"key":"6421_CR49","doi-asserted-by":"publisher","first-page":"186","DOI":"10.21037\/tcr-2025-aw-2392","volume":"15","author":"T Lin","year":"2026","unstructured":"Lin T, Chen X, Huang H, Zhang J, Xu Y, Lin J (2026) Pre-clinical anti-tumor activity and preliminary safety of METTL3 inhibitors STM2457 and UZH1a in neuroblastoma. Transl Cancer Res 15:186. https:\/\/doi.org\/10.21037\/tcr-2025-aw-2392","journal-title":"Transl Cancer Res"},{"key":"6421_CR50","doi-asserted-by":"publisher","first-page":"18114","DOI":"10.1021\/acs.jmedchem.5c01570","volume":"68","author":"H Tang","year":"2025","unstructured":"Tang H, Zhang R, Zhang A (2025) Small-molecule inhibitors targeting RNA m6A modifiers for cancer therapeutics: latest advances and future perspectives. J Med Chem 68:18114\u201318142. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01570","journal-title":"J Med Chem"},{"key":"6421_CR51","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/nejmp2109826","volume":"385","author":"M Shah","year":"2021","unstructured":"Shah M, Rahman A, Theoret MR, Pazdur R (2021) The drug-dosing conundrum in oncology: when less is more. N Engl J Med 385:1445\u20131447. https:\/\/doi.org\/10.1056\/nejmp2109826","journal-title":"N Engl J Med"},{"key":"6421_CR52","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1541-7786.mcr-17-0606","volume":"16","author":"PS Gowda","year":"2018","unstructured":"Gowda PS, Wildman BJ, Trotter TN, Xu X, Hao X, Hassan MQ, Yang Y (2018) Runx2 suppression by miR-342 and miR-363 inhibits multiple myeloma progression. Mol Cancer Res 16:1138\u20131148. https:\/\/doi.org\/10.1158\/1541-7786.mcr-17-0606","journal-title":"Mol Cancer Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06421-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:30:58Z","timestamp":1789979458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06421-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6421"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06421-9","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involving human participants was approved by the Medical Ethics Committee of Quzhou People\u2019s Hospital (Approval No.: 2022-041). All procedures were performed in accordance with the 1964 Helsinki Declaration and its later amendments. All participants provided the written informed consent.\u00a0Animal experiments were granted approval by the Animal Ethics Committee of Quzhou People\u2019s Hospital. All methods were carried out in accordance with relevant guidelines and regulations. This study was carried out in compliance with the ARRIVE guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"340"}}